Old Web
English
Sign In
Acemap
>
authorDetail
>
Shawna L. Weis
Shawna L. Weis
Center for Drug Evaluation and Research
Medicine
Melanoma
Ipilimumab
Cancer
Pneumonitis
3
Papers
120
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
“Regulatory Toxicology for Biopharmaceuticals: Preparing for Pre-IND Interactions and Avoiding IND Pitfalls for Oncology and Non-Oncology Products”
2021
Janice Lansita
Andrew McDougal
Jane Sohn
Shawna L. Weis
Show All
Source
Cite
Save
Citations (0)
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma
2017
Clinical Cancer Research
Meredith K. Chuk
Jennie T. Chang
Marc R. Theoret
Emmanuel Sampene
Kun He
Shawna L. Weis
Whitney S. Helms
Runyan Jin
Hongshan Li
Jingyu Yu
Hong Zhao
Liang Zhao
Mark Paciga
Deborah Schmiel
Rashmi Rawat
Patricia Keegan
Richard Pazdur
Show All
Source
Cite
Save
Citations (52)
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
2017
Clinical Cancer Research
Maitreyee Hazarika
Meredith K. Chuk
Marc R. Theoret
Sirisha Mushti
Kun He
Shawna L. Weis
Alexander Putman
Whitney S. Helms
Xianhua Cao
Hongshan Li
Hong Zhao
Liang Zhao
Joel E. Welch
Laurie Graham
Meredith Libeg
Rajeshwari Sridhara
Patricia Keegan
Richard Pazdur
Show All
Source
Cite
Save
Citations (68)
1